Latest news about Hikal
Hikal
189.62
-2.28(-1.19%)
Company Performance:
View Company Insights1D-1.19%
1M-2.62%
6M-25.02%
1Y-49.96%
5Y-57.16%
More news about Hikal
27May 26
HIKAL Anticipates Significant Contributions from New Specialty Chemicals and Personal Care Products Starting FY27, Backed by Expanded CDMO Pipeline
HIKAL anticipates significant contributions from new specialty chemicals and personal care products starting FY27. The company's growth outlook is further reinforced by an expanded CDMO pipeline, which is expected to drive stronger overall performance. These developments reflect HIKAL's strategic focus on diversifying its revenue streams and deepening its presence in high-value chemical and pharmaceutical segments.
14Apr 26
Hikal Limited Announces Superannuation of Crop Protection President Vimaldeep Kulshrestha
Hikal Limited announced the superannuation of Mr. Vimaldeep Kulshrestha, President-Crop Protection, effective April 14, 2026. The disclosure was made under SEBI's Listing Regulations to both BSE and NSE, with Mr. Kulshrestha ceasing employment from end of business hours on the specified date. The announcement represents a natural management transition in the company's crop protection division.
07Apr 26
Hikal Limited Files Mandatory SEBI Certificate for Q4 FY26 Dematerialisation Compliance
Hikal Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4 FY26, confirming compliance with dematerialisation processes. The certificate from registrar MUFG Intime India Private Limited validates proper handling of securities dematerialisation during the quarter ended March 31, 2026, fulfilling mandatory regulatory requirements.
18Feb 26
Hikal Limited Files SEBI PIT Regulations Disclosure for Promoter Entity LLP Conversion
Hikal Limited has submitted comprehensive disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015 regarding the conversion of promoter group entity Castilia Life Sciences Private Limited to LLP structure. The filing includes Form C disclosures detailing the transfer of 3,02,31,914 shares representing 24.52% shareholding worth ₹6,03,63,828 to the newly formed Castilia Life Sciences LLP following Ministry of Corporate Affairs approval dated 17th February 2026.
17Feb 26
Hikal Reports Q3 FY26 Results: Revenue ₹494 Cr, Approves Interim Dividend
Hikal Limited demonstrated strong operational recovery in Q3 FY26 with consolidated revenue of ₹494 crores and EBITDA of ₹83 crores (16.8% margin). The pharmaceutical segment showed significant improvement with ₹337 crores revenue and 12.3% EBIT margin, while crop protection faced margin pressures. The company approved interim dividend of ₹0.2 per share and is diversifying into specialty chemicals and animal health segments for future growth.
11Feb 26
Hikal Limited Confirms February 17, 2026 Record Date for Interim Dividend Payment
Hikal Limited has formally notified stock exchanges about February 17, 2026 record date for interim dividend payment following board approval on February 11, 2026. The company reported mixed Q3 FY26 results with revenue growth of 10.4% to ₹4,943 million but posted a net loss of ₹59 million compared to ₹173 million profit in the previous year.
27Dec 25
Hikal Discloses Revenue Recognition Irregularities Affecting Three Quarters, Reverses ₹80.70 Crore
Hikal Limited has revealed significant irregularities in revenue recognition affecting Q4FY25, Q1FY26, and Q2FY26. The issues, discovered during a fact-finding review, involve employee misconduct and document alterations. The most substantial impact was a revenue reversal of ₹80.70 crore in Q2FY26. The company clarified that all underlying sales transactions are genuine, with no embezzlement or misappropriation of funds. Hikal is evaluating reporting requirements and preparing to notify relevant authorities as needed.
05Dec 25
Hikal Ltd Shares Transfer to Castilia Life Sciences via Amalgamation Scheme
Castilia Life Sciences Private Limited has acquired a substantial stake in Hikal Limited through an amalgamation scheme approved under Section 233 of the Companies Act, 2013. The transaction involved the transfer of shares from Shri Rameshwara Investment Private Limited (8.32% stake) and Shri Badrinath Investment Private Limited (16.20% stake), totaling 24.52% of Hikal's total share capital. The scheme was approved on November 18, 2025, and became effective on December 1, 2025.
19Nov 25
Hikal Limited Reports Q2 FY26 Revenue of Rs. 319 Crores Amid Regulatory Challenges
Hikal Limited reported Q2 FY26 results with consolidated revenue of Rs. 319.00 crores and EBITDA of Rs. 8.00 crores. Performance was impacted by deferred sales of Rs. 80.00 crores due to a U.S. FDA warning letter. Pharmaceutical segment revenue was Rs. 190.00 crores with -9.20% EBIT margin, while Crop Protection segment revenue was Rs. 129.00 crores with negative EBIT. The company is addressing regulatory issues through remediation partners, CAPA plans, and dual-site validation for critical APIs. Management expects strong recovery in H2 FY26 with new product commercialization and improved demand visibility.
13Nov 25
HIKAL Reports Net Loss of 349 Million Rupees in Q2, Revenue Drops to 3.16 Billion
Hikal Limited reported a net loss of 349 million rupees in Q2, compared to a profit of 183 million rupees in the same period last year. Revenue declined to 3.16 billion rupees from 4.51 billion rupees year-over-year. The pharmaceutical segment faced challenges due to a US FDA warning letter, while the crop protection business experienced muted performance. Despite current difficulties, the company is implementing remediation efforts, strengthening its quality organization, and investing in new capabilities for future growth.
23Sept 25
Hikal Limited Reports Q1 Results: Pharmaceutical Segment Faces Temporary Setback
Hikal Limited reported a decline in Q1 FY24 performance due to challenges in its pharmaceutical segment. Consolidated revenue decreased 6.5% YoY to Rs 380.00 crore, with EBITDA margin falling to 6.5%. The company reported a net loss of Rs 23.00 crore. The pharmaceutical segment, contributing 53% of total revenue, was impacted by temporary customer offtake deferment following a US FDA OAI communication. The crop protection segment remained flat due to global overcapacity and Chinese competition. Despite challenges, Hikal successfully completed GMP audits at its Bangalore API facility and is working on remediation efforts. The company expects a recovery in Q3 and Q4, maintaining its full-year guidance.
22Sept 25
Hikal's Boardroom Battle: Proxy Firms Divided on Amit Kalyani's Reappointment
Hikal Ltd. is embroiled in a boardroom conflict over the reappointment of Amit Kalyani as a non-executive director. The dispute involves the Kalyani family (34% stake) and the Hiremath family (35% stake), with the remaining 31% held by institutional and retail investors. Proxy advisory firms have issued conflicting recommendations, with SES supporting Kalyani's reappointment and IiAS opposing it. The vote's outcome could significantly impact Hikal's corporate governance and future direction.
21Aug 25
Hikal Receives US FDA Warning Letter for Bengaluru Manufacturing Facility
Hikal Limited, an Indian pharmaceutical company, has received a warning letter from the US FDA regarding its Jigani, Bengaluru manufacturing facility. The warning follows an inspection conducted from February 3-7, 2025. Hikal has committed to addressing the regulatory concerns and working closely with the FDA to resolve the issues. The company's credit ratings have been reaffirmed by ICRA Limited, with a long-term rating of ICRA A+ (Stable) and a short-term rating of ICRA A1.
13Aug 25
Hikal Limited Reports Revenue Decline in Q1 Amid Regulatory Challenges
Hikal Limited's Q1 consolidated revenue decreased to Rs. 380.00 crores from Rs. 407.00 crores year-on-year. EBITDA fell to Rs. 25.00 crores with margins contracting to 6.50%. The pharmaceutical division saw an 11.70% revenue decline to Rs. 203.00 crores, reporting an EBIT loss of Rs. 27.00 crores due to deferred shipments following US FDA's OAI status for its Bangalore facility. The crop protection division remained stable with Rs. 178.00 crores revenue. Despite challenges, the company maintains its annual guidance and is implementing strategic initiatives including capacity expansion, dual-site manufacturing, and diversification into personal care products.
07Aug 25
HIKAL Reports Q1 Net Loss of ₹224 Million Amid Revenue Decline
Hikal Limited reported a net loss of ₹224.00 million in Q1, compared to a profit of ₹51.00 million in the same quarter last year. Revenue decreased by 6.5% to ₹3,804.00 million from ₹4,068.00 million year-over-year. EBITDA fell to ₹251.00 million from ₹580.00 million, with the EBITDA margin compressing to 6.60% from 14.26%. The Pharmaceuticals segment generated revenue of ₹2,026.00 million, while the Crop Protection segment contributed ₹1,778.00 million.
30Jul 25
Hikal's Jigani Unit Secures GMP Certification from Japan's PMDA
Hikal Limited's Jigani Unit in Bangalore has received Good Manufacturing Practices (GMP) certification from Japan's Pharmaceutical and Medical Device Agency (PMDA) for Active Pharmaceutical Ingredients (APIs). The certification was granted after a four-day inspection from May 19th to 22nd. This achievement could open doors to the Japanese pharmaceutical market and enhance Hikal's global credibility. The company officially informed stock exchanges about this development on July 30th.
17Jun 25
Hikal's Jigani Unit Passes Brazilian Anvisa GMP Audit
Hikal Limited's Jigani facility successfully passed a Good Manufacturing Practice (GMP) audit conducted by Brazilian Anvisa, Brazil's health regulatory agency. This achievement signifies compliance with Brazilian regulatory standards and could potentially open new opportunities for Hikal in the Brazilian pharmaceutical market. The approval aligns with Hikal's strategy to strengthen its position in the global pharmaceutical supply chain and demonstrates its ability to meet international regulatory requirements.
16Jun 25
Hikal's Jigani Facility Passes Brazilian ANVISA GMP Audit
Hikal Ltd successfully completed a Good Manufacturing Practice (GMP) audit by ANVISA, Brazil's regulatory authority, for its Jigani facility. This approval enhances Hikal's global credibility, opens opportunities for expansion in the Brazilian pharmaceutical market, and demonstrates the company's operational excellence. The ANVISA certification is expected to strengthen Hikal's position in the global pharmaceutical manufacturing landscape and may lead to increased collaborations with Brazilian and multinational pharmaceutical companies.
26May 25
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification
Hikal Ltd. announced that its Jigani, Karnataka manufacturing facility has been classified as 'Official Action Indicated' (OAI) by the U.S. FDA following an inspection. This classification suggests significant issues were identified, potentially leading to regulatory actions. Hikal has committed to working closely with the FDA to resolve the issues and emphasized its ongoing efforts to enhance compliance measures. The OAI status could potentially impact new product approvals and existing product supply from this facility.
23May 25
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification
Hikal Ltd's Jigani facility has been classified as 'Official Action Indicated' (OAI) following a U.S. FDA inspection, indicating significant objectionable conditions. The company has committed to addressing the FDA's concerns, working closely with the agency to resolve issues, and maintaining high-quality manufacturing standards. This classification may lead to increased regulatory scrutiny, require remediation efforts, and potentially impact new product approvals or existing product shipments from the facility.
14May 25
HIKAL's Q4 Results Showcase Robust Financial Growth
HIKAL Limited, a specialty chemicals and pharmaceuticals manufacturer, reported impressive Q4 financial results. EBITDA increased by 30.16% to 1.23 billion rupees, with EBITDA margin expanding to 22.34%. Consolidated net profit surged by 47.65% to 502 million rupees. The company demonstrated significant year-over-year improvements across key financial metrics, indicating strong operational efficiency and market positioning.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,782.20
(+0.12%)
6,623.00
(+0.40%)
4,420.90
(+1.87%)
1,401.30
(+0.19%)
1,089.00
(+0.41%)
1,278.20
(+0.84%)
2,267.70
(+0.80%)
2,336.10
(-0.72%)
1,462.30
(-0.09%)
1,446.80
(+1.37%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
